Eli Lilly & Co. (LLY): Looking Ahead To Expedition - Jefferies
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
Jefferies analyst, Jeffrey Holford, reiterated his Buy rating on shares of Eli Lilly (NYSE: LLY) but cut his price target to $100.00 (from $105.00) after Q3 missed expectations.
The analyst cut 2016E-2020E revenue estimates by 2%-3% after incremental pricing pressure on Humalog, competition and LOEs adversely pressured results. 2016 non-GAAP EPS of $3.56 is unchanged but 2017E-2020E non-GAAP EPS is reduced by 1%-5%.
The Buy thesis on LLY is unchanged because it is focused around its new product launch momentum combined with tremendous operating leverage potential. EXPEDITION-3 should be a stronger driver of near term sentiment as well.
Shares of Eli Lilly closed at $76.76 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Newell Brands (NWL): Cutting PT - Jefferies
- BWS Financial Cuts Price Target on Sigma Designs (SIGM) to $5.00
- Deutsche Bank Downgrades MGM Growth Properties (MGP) to Hold
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS Change, Analyst PT Change, Earnings
Related EntitiesJefferies & Co
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!